{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:15:54Z","timestamp":1790115354464,"version":"4.0.1"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[1998,8,1]],"date-time":"1998-08-01T00:00:00Z","timestamp":901929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1998,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The broad antibacterial spectrum and the low incidence of seizures in meropenem-treated patients qualifies meropenem for therapy of bacterial meningitis. The present study evaluates concentrations in ventricular cerebrospinal fluid (CSF) in the absence of pronounced meningeal inflammation. Patients with occlusive hydrocephalus caused by cerebrovascular diseases, who had undergone external ventriculostomy (\n                    <jats:italic>n<\/jats:italic>\n                    = 10, age range 48 to 75 years), received 2 g of meropenem intravenously over 30 min. Serum and CSF were drawn repeatedly and analyzed by liquid chromatography-mass spectroscopy. Pharmacokinetics were determined by noncompartmental analysis. Maximum concentrations in serum were 84.7 \u00b1 23.7 \u03bcg\/ml. A CSF maximum (\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>maxCSF<\/jats:sub>\n                    ) of 0.63 \u00b1 0.50 \u03bcg\/ml (mean \u00b1 standard deviation) was observed 4.1 \u00b1 2.6 h after the end of the infusion. C\n                    <jats:sub>maxCSF<\/jats:sub>\n                    and the area under the curve for CSF (AUC\n                    <jats:sub>CSF<\/jats:sub>\n                    ) depended on the AUC for serum (AUC\n                    <jats:sub>S<\/jats:sub>\n                    ), the CSF-to-serum albumin ratio, and the CSF leukocyte count. Elimination from CSF was considerably slower than from serum (half-life at \u03b2 phase [\n                    <jats:italic>t<\/jats:italic>\n                    <jats:sub>1\/2\u03b2<\/jats:sub>\n                    ] of 7.36 \u00b1 2.89 h in CSF versus\n                    <jats:italic>t<\/jats:italic>\n                    <jats:sub>1\/2\u03b2<\/jats:sub>\n                    of 1.69 \u00b1 0.60 h in serum). The AUC\n                    <jats:sub>CSF<\/jats:sub>\n                    \/AUC\n                    <jats:sub>S<\/jats:sub>\n                    ratio for meropenem, as a measure of overall CSF penetration, was 0.047 \u00b1 0.022. The AUC\n                    <jats:sub>CSF<\/jats:sub>\n                    \/AUC\n                    <jats:sub>S<\/jats:sub>\n                    ratio for meropenem was similar to that for other \u03b2-lactam antibiotics with a low binding to serum proteins. The concentration maxima of meropenem in ventricular CSF observed in this study are high enough to kill fully susceptible pathogens. They may not be sufficient to kill bacteria with a reduced sensitivity to carbapenems, although clinical success has been reported for patients with meningitis caused by penicillin-resistant pneumococci and\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    .\n                  <\/jats:p>","DOI":"10.1128\/aac.42.8.2012","type":"journal-article","created":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T20:33:13Z","timestamp":1539030793000},"page":"2012-2016","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":55,"title":["Disposition and Elimination of Meropenem in Cerebrospinal Fluid of Hydrocephalic Patients with External Ventriculostomy"],"prefix":"10.1128","volume":"42","author":[{"given":"Roland","family":"Nau","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Department of Neurology, University of Go\u0308ttingen, D-37075 Go\u0308ttingen,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Lassek","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Neurology, University of Go\u0308ttingen, D-37075 Go\u0308ttingen,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Kinzig-Schippers","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Institute of Biomedical &amp; Pharmaceutical Research, D-90562 Nu\u0308rnberg-Heroldsberg,2 Germany, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Thiel","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Klinik fu\u0308r Psychologie und Psychotherapie, Universita\u0308t Innsbruck, A-6020 Innsbruck, Austria3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilmar W.","family":"Prange","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Neurology, University of Go\u0308ttingen, D-37075 Go\u0308ttingen,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"So\u0308rgel","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Institute of Biomedical &amp; Pharmaceutical Research, D-90562 Nu\u0308rnberg-Heroldsberg,2 Germany, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.12.2779"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2165\/00003495-199244030-00008","article-title":"Imipenem\/cilastatin: a reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.","volume":"44","author":"Buckley M. M.","year":"1992","unstructured":"Buckley M. M. Brogden R. N. Barradell L. B. Goa K. L. Imipenem\/cilastatin: a reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 44 1992 408 444","journal-title":"Drugs"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.9.2158"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/jac\/32.6.922","article-title":"Meropenem treatment of post-traumatic meningitis due to Pseudomonas aeruginosa.","volume":"32","author":"Chmelik V.","year":"1993","unstructured":"Chmelik V. Gutvirth J. Meropenem treatment of post-traumatic meningitis due to Pseudomonas aeruginosa. J. Antimicrob. Chemother. 32 1993 922 923","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jac\/34.1.175","article-title":"Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges.","volume":"34","author":"Dagan R.","year":"1994","unstructured":"Dagan R. Velghe L. Rodda J. L. Klugman K. P. Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges. J. Antimicrob. Chemother. 34 1994 175 179","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_7_2","unstructured":"Dealy\n              D. H.\n              Duma\n              R. J.\n              Tartaglione\n              T. A.\n              Beightol\n              L. A.\n              Patterson\n              P. M.\n          Penetration of primaxin (N-formimidoyl thienamycin and cilastatin) into human cerebrospinal fluid abstr. S-78-4.\n          Abstracts of the 14th International Congress on Chemotherapy Kyoto Japan\n          1985"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/0140-6736(92)90714-E","article-title":"High dose meropenem in meningitis due to Pseudomonas aeruginosa.","volume":"339","author":"Donnelly J. P.","year":"1992","unstructured":"Donnelly J. P. Horrevorts A. M. Sauerwein R. W. de Pauw B. E. High dose meropenem in meningitis due to Pseudomonas aeruginosa. Lancet 339 1992 1117","journal-title":"Lancet"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Edwards J. R. 1995. Meropenem: a microbiological overview. J. Antimicrob. Chemother. 36 (Suppl. A) : 1\u201317.","DOI":"10.1093\/jac\/36.suppl_A.1"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3171\/jns.1983.59.3.0389","article-title":"Cerebrospinal fluid shunt infections. A review of 35 infections in 32 patients.","volume":"59","author":"Forward K. R.","year":"1983","unstructured":"Forward K. R. Fewer H. D. Stiver H. G. Cerebrospinal fluid shunt infections. A review of 35 infections in 32 patients. J. Neurosurg. 59 1983 389 394","journal-title":"J. Neurosurg."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","unstructured":"Gietz\n              J.\n              Prange\n              H.\n              Nau\n              R.\n          Pneumokokken-Sepsis und -Meningitis bei Erwachsenen nach Splenektomie\n          Bakterielle ZNS-Erkrankungen bei systemischen Infektionen.\n              Prange\n              H.\n              Bitsch\n              A.\n          1997\n          17\n          29\n          Steinkopff\n          Darmstadt Germany","DOI":"10.1007\/978-3-642-93694-4_3"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Hutchinson M. K. L. Faulkner P. J. Turner S. J. Haworth W. Sheikh H. Nadler and D. H. Pitkin. 1995. A compilation of meropenem tissue distribution data. J. Antimicrob. Chemother. 36 (Suppl. A) : 43\u201356.","DOI":"10.1093\/jac\/36.suppl_A.43"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.5.1140"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/000992287301200216","article-title":"Acute bacterial meningitis with absent or minimal cerebrospinal fluid abnormalities.","volume":"12","author":"Moore C. M.","year":"1973","unstructured":"Moore C. M. Ross M. Acute bacterial meningitis with absent or minimal cerebrospinal fluid abnormalities. Clin. Pediatr. 12 1973 117 118","journal-title":"Clin. Pediatr."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(90)90055-Z"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","unstructured":"Nairn K. G. L. Shepherd and J. R. Edwards. 1995. Efficacy of meropenem in experimental meningitis. J. Antimicrob. Chemother. 36 (Suppl. A) : 73\u201384.","DOI":"10.1093\/jac\/36.suppl_A.73"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.5.987"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/BF00203787","article-title":"Estimation of steady state antibiotic concentration in cerebrospinal fluid from single-dose kinetics.","volume":"49","author":"Nau R.","year":"1996","unstructured":"Nau R. Prange H. W. Estimation of steady state antibiotic concentration in cerebrospinal fluid from single-dose kinetics. Eur. J. Clin. Pharmacol. 49 1996 407 409","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.3.763"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.7.1518"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.3.593"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0022-510X(94)90052-3","article-title":"Lipophilicity at pH 7.4 and molecular size govern the entry of not actively transported drugs into the cerebrospinal fluid in humans with uninflamed meninges.","volume":"122","author":"Nau R.","year":"1994","unstructured":"Nau R. S\u00f6rgel F. Prange H. W. Lipophilicity at pH 7.4 and molecular size govern the entry of not actively transported drugs into the cerebrospinal fluid in humans with uninflamed meninges. J. Neurol. Sci. 122 1994 61 65","journal-title":"J. Neurol. Sci."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3171\/jns.1984.61.2.0328","article-title":"Shunt fluid examination: risks and benefits in the evaluation of shunt malformation and infection.","volume":"61","author":"Noetzel M. J.","year":"1984","unstructured":"Noetzel M. J. Baker R. P. Shunt fluid examination: risks and benefits in the evaluation of shunt malformation and infection. J. Neurosurg. 61 1984 328 332","journal-title":"J. Neurosurg."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","unstructured":"Norrby S. R. P. A. Newell K. L. Faulkner and W. Lesky. 1995. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J. Antimicrob. Chemother. 36 (Suppl. A) : 207\u2013223.","DOI":"10.1093\/jac\/36.suppl_A.207"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.6.1320"},{"key":"e_1_3_2_26_2","first-page":"105","article-title":"Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae.","volume":"40","author":"Pikis A.","year":"1997","unstructured":"Pikis A. Donkersloot J. A. Akram S. Keith J. M. Campos J. M. Rodriguez W. J. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother. 40 1997 105 108","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1023\/A:1015854902915","article-title":"Modeling the enhanced uptake of zidovudine (AZT) into cerebrospinal fluid. 1. Effect of probenecid.","volume":"7","author":"Sawchuk R. J.","year":"1990","unstructured":"Sawchuk R. J. Hedaya M. A. Modeling the enhanced uptake of zidovudine (AZT) into cerebrospinal fluid. 1. Effect of probenecid. Pharm. Res. 7 1990 332 338","journal-title":"Pharm. Res."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","unstructured":"Schmutzhard E. K. J. Williams G. Vukmirovits V. Chmelik B. Pfausler A. Featherstone and the Meropenem Meningitis Study Group. 1995. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. J. Antimicrob. Chemother. 36 (Suppl. A) : 85\u201397.","DOI":"10.1093\/jac\/36.suppl_A.85"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/infdis\/149.4.568","article-title":"Antibacterial activity of \u03b2-lactam antibiotics in experimental meningitis due to Streptococcus pneumoniae.","volume":"149","author":"T\u00e4uber M. G.","year":"1984","unstructured":"T\u00e4uber M. G. Doroshow C. A. Hackbarth C. J. Rusnak M. G. Drake T. A. Sande M. A. Antibacterial activity of \u03b2-lactam antibiotics in experimental meningitis due to Streptococcus pneumoniae. J. Infect. Dis. 149 1984 568 574","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/00003495-199550010-00007","article-title":"Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.","volume":"50","author":"Wiseman L. R.","year":"1995","unstructured":"Wiseman L. R. Wagstaff A. J. Brogden R. N. Bryson H. M. Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 50 1995 73 101","journal-title":"Drugs"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","unstructured":"Zeneca GmbH. 1997. Data on file.","DOI":"10.1016\/S0294-3506(97)87034-2"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.42.8.2012","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.42.8.2012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T10:49:37Z","timestamp":1645440577000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.42.8.2012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[1998,8]]}},"alternative-id":["10.1128\/AAC.42.8.2012"],"URL":"https:\/\/doi.org\/10.1128\/aac.42.8.2012","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,8]]},"assertion":[{"value":"1997-11-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-05-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-08-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}